Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Identification of Broad-Spectrum Antiviral Compounds by Targeting Viral Entry.

Mazzon M, Ortega-Prieto AM, Imrie D, Luft C, Hess L, Czieso S, Grove J, Skelton JK, Farleigh L, Bugert JJ, Wright E, Temperton N, Angell R, Oxenford S, Jacobs M, Ketteler R, Dorner M, Marsh M.

Viruses. 2019 Feb 20;11(2). pii: E176. doi: 10.3390/v11020176.

2.

Cross-Protective Immune Responses Induced by Sequential Influenza Virus Infection and by Sequential Vaccination With Inactivated Influenza Vaccines.

Dong W, Bhide Y, Sicca F, Meijerhof T, Guilfoyle K, Engelhardt OG, Boon L, de Haan CAM, Carnell G, Temperton N, de Vries-Idema J, Kelvin D, Huckriede A.

Front Immunol. 2018 Oct 9;9:2312. doi: 10.3389/fimmu.2018.02312. eCollection 2018.

3.

A naturally protective epitope of limited variability as an influenza vaccine target.

Thompson CP, Lourenço J, Walters AA, Obolski U, Edmans M, Palmer DS, Kooblall K, Carnell GW, O'Connor D, Bowden TA, Pybus OG, Pollard AJ, Temperton NJ, Lambe T, Gilbert SC, Gupta S.

Nat Commun. 2018 Sep 21;9(1):3859. doi: 10.1038/s41467-018-06228-8.

4.

Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.

Gallinaro A, Borghi M, Bona R, Grasso F, Calzoletti L, Palladino L, Cecchetti S, Vescio MF, Macchia D, Morante V, Canitano A, Temperton N, Castrucci MR, Salvatore M, Michelini Z, Cara A, Negri D.

Front Immunol. 2018 Feb 5;9:171. doi: 10.3389/fimmu.2018.00171. eCollection 2018.

5.

Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis.

Ferrara F, Temperton N.

Methods Protoc. 2018 Jan 22;1(1). pii: E8. doi: 10.3390/mps1010008.

6.

The Use of Hyperimmune Chicken Reference Sera Is Not Appropriate for the Validation of Influenza Pseudotype Neutralization Assays.

Ferrara F, Molesti E, Scott S, Cattoli G, Temperton N.

Pathogens. 2017 Sep 25;6(4). pii: E45. doi: 10.3390/pathogens6040045.

7.

Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge.

Tully CM, Chinnakannan S, Mullarkey CE, Ulaszewska M, Ferrara F, Temperton N, Gilbert SC, Lambe T.

J Immunol. 2017 Jul 19. pii: ji1600939. doi: 10.4049/jimmunol.1600939. [Epub ahead of print]

PMID:
28724579
8.

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.

Alharbi NK, Padron-Regalado E, Thompson CP, Kupke A, Wells D, Sloan MA, Grehan K, Temperton N, Lambe T, Warimwe G, Becker S, Hill AVS, Gilbert SC.

Vaccine. 2017 Jun 27;35(30):3780-3788. doi: 10.1016/j.vaccine.2017.05.032. Epub 2017 Jun 1.

9.

Chimeric influenza haemagglutinins: Generation and use in pseudotype neutralization assays.

Ferrara F, Temperton N.

MethodsX. 2016 Dec 15;4:11-24. doi: 10.1016/j.mex.2016.12.001. eCollection 2017.

10.

The Optimisation of Pseudotyped Viruses for the Characterisation of Immune Responses to Equine Influenza Virus.

Scott SD, Kinsley R, Temperton N, Daly JM.

Pathogens. 2016 Dec 15;5(4). pii: E68.

11.

Stalking influenza by vaccination with pre-fusion headless HA mini-stem.

Valkenburg SA, Mallajosyula VV, Li OT, Chin AW, Carnell G, Temperton N, Varadarajan R, Poon LL.

Sci Rep. 2016 Mar 7;6:22666. doi: 10.1038/srep22666.

12.

Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.

Mullin J, Ahmed MS, Sharma R, Upile N, Beer H, Achar P, Puksuriwong S, Ferrara F, Temperton N, McNamara P, Lambe T, Gilbert SC, Zhang Q.

Vaccine. 2016 Mar 29;34(14):1688-95. doi: 10.1016/j.vaccine.2016.02.028. Epub 2016 Feb 20.

PMID:
26902548
13.

Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods.

Vrdoljak A, Allen EA, Ferrara F, Temperton NJ, Crean AM, Moore AC.

J Control Release. 2016 Mar 10;225:192-204. doi: 10.1016/j.jconrel.2016.01.019. Epub 2016 Jan 14.

PMID:
26774221
14.

Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody.

Xiong X, Corti D, Liu J, Pinna D, Foglierini M, Calder LJ, Martin SR, Lin YP, Walker PA, Collins PJ, Monne I, Suguitan AL Jr, Santos C, Temperton NJ, Subbarao K, Lanzavecchia A, Gamblin SJ, Skehel JJ.

Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):9430-5. doi: 10.1073/pnas.1510816112. Epub 2015 Jul 13.

15.

Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype.

Mallajosyula VV, Citron M, Ferrara F, Temperton NJ, Liang X, Flynn JA, Varadarajan R.

Front Immunol. 2015 Jun 26;6:329. doi: 10.3389/fimmu.2015.00329. eCollection 2015.

16.

Antiviral therapies against Ebola and other emerging viral diseases using existing medicines that block virus entry.

Long J, Wright E, Molesti E, Temperton N, Barclay W.

Version 2. F1000Res. 2015 Jan 29 [revised 2015 Jan 1];4:30. doi: 10.12688/f1000research.6085.2. eCollection 2015.

17.

Pseudotype-based neutralization assays for influenza: a systematic analysis.

Carnell GW, Ferrara F, Grehan K, Thompson CP, Temperton NJ.

Front Immunol. 2015 Apr 29;6:161. doi: 10.3389/fimmu.2015.00161. eCollection 2015. Review.

18.

The use of pseudotypes to study viruses, virus sero-epidemiology and vaccination.

Bentley EM, Mather ST, Temperton NJ.

Vaccine. 2015 Jun 12;33(26):2955-62. doi: 10.1016/j.vaccine.2015.04.071. Epub 2015 Apr 30.

PMID:
25936665
19.

Bat and pig IFN-induced transmembrane protein 3 restrict cell entry by influenza virus and lyssaviruses.

Benfield CT, Smith SE, Wright E, Wash RS, Ferrara F, Temperton NJ, Kellam P.

J Gen Virol. 2015 May;96(Pt 5):991-1005. doi: 10.1099/vir.0.000058. Epub 2015 Jan 22.

20.

Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.

Ahmed MS, Jacques LC, Mahallawi W, Ferrara F, Temperton N, Upile N, Vaughan C, Sharma R, Beer H, Hoschler K, McNamara PS, Zhang Q.

Antiviral Res. 2015 Feb;114:106-12. doi: 10.1016/j.antiviral.2014.12.008. Epub 2014 Dec 13.

PMID:
25513756

Supplemental Content

Loading ...
Support Center